on 05 Feb 2024
Last Applicant/ Owned by
MBRACE THERAPEUTICS INC.
4660 La Jolla Village Dr Ste 950San Diego, CA 92122-4615
US
Serial Number
2308748 filed on 05th Feb 2024
Correspondent Address
5276, boul. Saint-LaurentMontréal
QUÉBEC
CA
H2T1S1
MBRACE THERAPEUTICS & DESIGN
Vienna Information
27 . 5 . 1
Letters presenting a special form of writingLettres présentant un graphisme spécial
27 . 5 . 14
Letters repeated by mirror effect or symmetrically in any positionLettres répétées par effet de miroir ou symétriquement dans une position quelconque
27 . 5 . 22
Monograms formed of intertwined, overlapping or otherwise combined lettersMonogrammes formés par des lettres enlacées, se chevauchant ou combinées autrement
26 . 1 . 1
CirclesCercles
26 . 1 . 3
One circle or ellipseUn cercle ou une ellipse
26 . 1 . 18
Circles or ellipses containing one or more lettersCercles ou ellipses contenant une ou plusieurs lettres
26 . 1 . 24
Circles or ellipses with dark surfaces or parts of surfacesCercles ou ellipses avec surface ou partie de la surface foncée
26 . 1 . 26
Circles or ellipses with cutout areasCercles ou ellipses avec des zones découpées
Trademark usage description
antibody drug conjugate being medicines which deliver chemotherapy agents to kill cancer cells and/or abort cell multiplication; tumor suppressing age Read MoreClassification Information
Class [005]
Antibody drug conjugate being medicines which deliver chemotherapy agents to kill cancer cells and/or abort cell multiplication; Tumor suppressing agents; Pharmaceutical preparations for suppressing tumors.
Classification kind code
12
Class [042]
Computer and scientific
Comment text
CIPO Classification Code
Classification kind code
Nice
Class [044]
Antibody testing for medical diagnostic or treatment purposes.
Classification kind code
12
Mark Details
Serial Number
2308748
Mark Type
Trademark
Legal History
| Action Taken | Status |
|---|---|
| Submitted for opposition 287 on 29th Feb 2024 | Pre-Assessment Letter Sent |
| Submitted for opposition 30 on 05th Feb 2024 | Filed |
| Submitted for opposition 1 on 05th Feb 2024 | Created |
| Submitted for opposition 31 on 05th Feb 2024 | Formalized |